Viking Therapeutics, Inc. VKTX
35.56
(1.19)
(3.24%)
as of 25 Sep
- Market cap
- $4.3B
- P/E
- 0.0×
Follow VKTX
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(29.23%) | (47.34%) | (70.04%) | (88.85%) | |
| (28.31%) | (44.29%) | (64.04%) | (79.24%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(33.31%) | (56.29%) | (94.11%) | (131.11%) | |
Free Cash Flow per Share |
(2.00) | (2.47) | (2.94) | (3.60) | |
Free Cash Flow |
(224.58) | (278.68) | (340.33) | (418.44) | |
| Other line items | |||||
Cash ROIC |
(15.73%) | (20.72%) | (30.80%) | (45.98%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.95 | 0.77 | 0.72 | 0.78 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.00) | (2.47) | (2.94) | (3.60) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates